Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:169 |
Name | neuroendocrine tumor |
Definition | An endocrine gland cancer that has_material_basis_in neuroendocrine cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer neuroendocrine tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
RB1 loss | Sirolimus | neuroendocrine tumor | sensitive | detail... |
CDKN2A loss | ZK 304709 | neuroendocrine tumor | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | neuroendocrine tumor | sensitive | detail... |
BRAF V600E | Trametinib + Vemurafenib | neuroendocrine tumor | predicted - sensitive | detail... |
MLH1 negative | Pembrolizumab | neuroendocrine tumor | sensitive | detail... |
MSH6 negative | Pembrolizumab | neuroendocrine tumor | sensitive | detail... |
RET fusion | Selpercatinib | neuroendocrine tumor | sensitive | detail... |
EML4 - ALK | Crizotinib | neuroendocrine tumor | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00926640 | Phase I | Belinostat + Cisplatin + Etoposide | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | Completed | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | GBR | FRA | ESP | 0 |
NCT01466036 | Phase II | Cabozantinib | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | Completed | USA | 0 |
NCT01841736 | Phase II | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02063958 | Phase I | SNX-5422 | Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors | Completed | USA | 0 |
NCT02205515 | Phase Ib/II | Everolimus | An Open Label, Single-Centre, Phase II Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis | Completed | CAN | 0 |
NCT02250885 | Phase II | Selinexor | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | Completed | USA | 0 |
NCT02259725 | Phase II | Regorafenib | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | Completed | USA | 0 |
NCT02279433 | Phase I | Taletrectinib | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Completed | USA | 0 |
NCT02315625 | Phase II | Everolimus Sunitinib | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | Terminated | USA | 0 |
NCT02399215 | Phase II | Nintedanib | Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | Completed | USA | 0 |
NCT02402920 | Phase I | Carboplatin + Etoposide + Pembrolizumab Cisplatin | Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02420691 | Phase II | Ribociclib | LEE011 in Neuroendocrine Tumors of Foregut Origin | Completed | USA | 0 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Completed | USA | SWE | ITA | GBR | FRA | ESP | DEU | CHE | BEL | 0 |
NCT02487095 | Phase Ib/II | Berzosertib Topotecan | Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02489903 | Phase II | Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel | RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens | Completed | USA | 0 |
NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | POL | NOR | NLD | ITA | ISR | FRA | ESP | DNK | DEU | BRA | AUS | 9 |
NCT02754297 | Phase II | lutetium Lu 177 dotatate | Personalized PRRT of Neuroendocrine Tumors (P-PRRT) | Active, not recruiting | CAN | 0 |
NCT02795858 | Phase II | Octreotide + Ramucirumab | A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors | Active, not recruiting | USA | 0 |
NCT02831179 | Phase I | Capecitabine + Temozolomide + Veliparib | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | Withdrawn | 0 | |
NCT02875223 | Phase I | CC-90011 | A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | Terminated | ITA | GBR | FRA | ESP | 1 |
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
NCT02939651 | Phase II | Pembrolizumab | A Study of Pembrolizumab in Patients With Neuroendocrine Tumors | Completed | USA | 0 |
NCT02955069 | Phase II | Spartalizumab | Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 1 |
NCT03014297 | Phase I | Everolimus + Fosbretabulin | Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression | Terminated | USA | 0 |
NCT03034200 | Phase II | ONC201 | Phase 2 Study of ONC201 in Neuroendocrine Tumors | Completed | USA | 0 |
NCT03070301 | Phase II | Everolimus + Ribociclib | A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors | Completed | USA | 0 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03095274 | Phase II | Durvalumab Tremelimumab | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) | Completed | ESP | 0 |
NCT03211988 | Phase II | Entinostat | Entinostat Neuroendocrine (NE) Tumor | Terminated | USA | 0 |
NCT03289741 | FDA approved | Lanreotide acetate + Octreotide | A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | Completed | USA | 0 |
NCT03290079 | Phase II | Pembrolizumab | Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas | Completed | USA | 0 |
NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03375320 | Phase III | Cabozantinib | Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03411915 | Phase I | XmAb18087 | A Study of XmAb18087 in Subjects With NET and GIST | Completed | USA | 0 |
NCT03420521 | Phase II | Ipilimumab + Nivolumab | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | Terminated | USA | 0 |
NCT03457948 | Phase II | Pembrolizumab Pembrolizumab + Yttrium-90 microsphere therapy | Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases | Active, not recruiting | USA | 0 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03950609 | Phase II | Everolimus + Lenvatinib | Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors | Active, not recruiting | USA | 0 |
NCT03980925 | Phase II | Carboplatin + Etoposide + Nivolumab | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | Active, not recruiting | ESP | 0 |
NCT04197310 | Phase II | Cabozantinib + Nivolumab | Cabozantinib and Nivolumab for Carcinoid Tumors | Completed | USA | 0 |
NCT04234568 | Phase I | lutetium Lu 177 dotatate + Triapine | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
NCT04400474 | Phase II | Atezolizumab + Cabozantinib | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) | Active, not recruiting | ESP | 0 |
NCT04412629 | Phase II | Cabozantinib | Cabozantinib in High Grade Neuroendocrine Neoplasms | Recruiting | USA | 0 |
NCT04427787 | Phase II | Cabozantinib + Lanreotide acetate | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) | Unknown status | ITA | 0 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Unknown status | AUS | 2 |
NCT04471727 | Phase Ib/II | Atezolizumab + HPN328 HPN328 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | Recruiting | USA | 0 |
NCT04524208 | Phase II | Cabozantinib | A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 (CABONEN) | Active, not recruiting | DEU | AUT | 0 |
NCT04525638 | Phase II | lutetium Lu 177 dotatate + Nivolumab | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours | Unknown status | ESP | 0 |
NCT04579679 | Phase II | Surufatinib | Open-Label Surufatinib in European Patients With NET | Active, not recruiting | USA | NOR | ITA | GBR | FRA | ESP | DEU | 0 |
NCT04579757 | Phase Ib/II | Surufatinib + Tislelizumab | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04614766 | Phase Ib/II | 131I-MIBG + lutetium Lu 177 dotatate lutetium Lu 177 dotatate | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3) | Withdrawn | USA | 0 |
NCT04750954 | Phase I | lutetium Lu 177 dotatate + Peposertib | Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
NCT04776876 | Phase II | Retifanlimab + Telotristat etiprate | Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome | Withdrawn | 0 | |
NCT04802174 | Phase Ib/II | Berzosertib + Lurbinectedin | A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers | Recruiting | USA | 0 |
NCT04814732 | Expanded access | Surufatinib | Expanded Access Program of Surufatinib | No longer available | USA | 0 |
NCT05000294 | Phase Ib/II | Atezolizumab + Tivozanib | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Recruiting | USA | 0 |
NCT05178693 | Phase I | Decitabine and Cedazuridine + lutetium Lu 177 dotatate | Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana) | Recruiting | GBR | 0 |
NCT05268666 | Phase Ib/II | JBI-802 | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05289856 | Phase II | Avelumab + Cabozantinib | Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3) | Active, not recruiting | DEU | 0 |
NCT05420636 | Phase II | ORY-1001 + Paclitaxel | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | Recruiting | USA | 0 |
NCT05546268 | Phase Ib/II | MRT-2359 | Study of Oral MRT-2359 in Selected Cancer Patients | Recruiting | USA | CAN | 0 |
NCT05554003 | Phase II | Temozolomide | Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study (MeTe) | Recruiting | ITA | 0 |
NCT05619744 | Phase I | RO7616789 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | Recruiting | USA | POL | ESP | DNK | 1 |
NCT05636618 | Phase Ib/II | [212Pb]VMT01 | Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors ([212-Pb]-VMT) | Recruiting | USA | 0 |
NCT05691491 | Phase Ib/II | M1774 + Temozolomide | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | Recruiting | USA | 0 |
NCT05724108 | Phase II | lutetium Lu 177 dotatate lutetium Lu 177 dotatate + Triapine | Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT05746208 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT05773274 | Phase Ib/II | Everolimus lutetium Lu 177 dotatate | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial | Recruiting | USA | CAN | 0 |
NCT05870423 | Phase I | lutetium Lu 177 dotatate + Olaparib | Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors (PRRT-PARPi) | Recruiting | NLD | 0 |
NCT05918302 | Phase III | 177Lu-edotreotide Everolimus | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (LEVEL) | Recruiting | ITA | FRA | ESP | 0 |
NCT06041516 | Phase I | ADCT-701 | Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas | Recruiting | USA | 0 |
NCT06148636 | Phase I | 212Pb-VMT-alpha-NET | A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
NCT06232564 | Phase II | Lenvatinib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs (PELICAN) | Recruiting | GBR | 0 |
NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |
NCT06395402 | Phase II | lutetium Lu 177 dotatate | 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID) | Recruiting | USA | 0 |
NCT06400485 | Phase I | AMT-676 | AMT-676 in Patients With Advanced Solid Tumors | Recruiting | AUS | 1 |
NCT06472388 | Phase II | Everolimus | Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors (EVENET) | Recruiting | BRA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |